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analysis was performed with the Mainland-Gart test and
the Fisher exact test. Subjects were also asked to ﬁll out
a generic QoL questionnaire (the Functional Assessment
of Cancer Therapy-General [FACT-G]) at the beginning
of each cycle and on day 14 with the Subject Outcome
Questionnaire (SOQ), which evaluates levels of pain, dis-
comfort, inconvenience, satisfaction, etc. RESULTS: Of
the 76 randomised patients, 74 took study medication, 4
discontinued, making a total of 70 evaluable subjects.
Overall, 58 patients preferred pegﬁlgrastim (83%; p <
0.001) after 2 cycles. Signiﬁcantly more patients preferred
pegﬁlgrastim when starting with ﬁlgrastim ﬁrst (94%
versus 73%, p < 0.001), indicating a clear sequential
effect. The main reason for the overall preference of peg-
ﬁlgrastim was dosing simpliﬁcation, safety and less pain.
Overall, mean SOQ scores were better in the pegﬁlgras-
tim arm (87.5% versus 78.9% in the ﬁlgrastim arm, p <
0.05). Differences in speciﬁc SOQ areas were predomi-
nantly found in the pegﬁlgrastim arm. FACT-G scores
showed no signiﬁcant differences between treatment arms
and cycles. CONCLUSION: Subjects demonstrated a
very strong preference for pegﬁlgrastim (83%), primarily
because of dosing simpliﬁcation. A higher proportion also
reported less pain, discomfort and inconvenience, as well
as greater treatment satisfaction.
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OBJECTIVES: Treatment Outcomes in Pain Survey
(TOPS) characterizes pain and health-related quality of
life (HRQL) with chronic nonmalignant pain (CNMP).
TOPS has 8 subscales from SF-36 Health Survey and 14
TOPS domains measuring physical, functional, and psy-
chosocial status. We evaluated TOPS in cancer-related
pain. METHODS: TOPS was administered to 150
patients with advanced cancer-related pain at three US
academic hospitals. Data were collected on demographic
variables, primary site of cancer, and cancer treatment
status. Pain was measured on a visual analogue scale.
Internal consistency reliability (Cronbach’s alpha) was
assessed for the 8 TOPS SF-36 subscales and 14 TOPS
domains. Cases were compared by treatment status, phys-
iologic sources of pain, and pain severity using Student-t
tests and the Mann-Whitney U tests. RESULTS: Physical,
functional, and psychosocial status differed by treatment
status. There were no signiﬁcant differences in TOPS SF-
36 and TOPS domains for subjects experiencing neuro-
pathic compared to non-neuropathic pain. However,
those with somatic pain reported greater Body Pain (p =
0.001) and Pain Symptoms (p < 0.05), and had worse
Total Pain Experience (p < 0.05). Greater pain was asso-
ciated with signiﬁcantly poorer outcomes on 5 of the 8
SF-36 subscales, with more Pain Symptoms (p < 0.001),
greater family disruptions (p < 0.001), poorer Passive
Coping (p < 0.05), and less Patient Satisfaction with Out-
comes (p < 0.01). Reliability for SF-36 subscales and
TOPS domains were all > 0.70, similar to prior TOPS
usage in CNMP. CONCLUSIONS: TOPS demonstr-
ated acceptable reliability with cancer-related pain and
detected signiﬁcant differences by treatment status, 
source of pain, and pain severity. That TOPS SF-36 and
TOPS domains differed by pain severity supports its
validity as a measure to assess pain outcomes and HRQL
in cancer. TOPS may also be a useful clinical tool to 
identify patients at risk for impaired physical function,
symptoms, emotional distress, disruptions in social rela-
tionships, and negative perceptions of satisfaction with
health care.
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OBJECTIVE: To examine the association between hemo-
globin levels and anemia diagnosis and to determine the
hemoglobin level that is most likely to trigger diagnosis
in oncology patients. METHODS: Members of a large US
health plan with an oncology diagnosis and chemo-
therapy claims between January 1, 2002 and February
28, 2002 were included in this retrospective claims data-
base analysis. Medical and laboratory claims were exam-
ined to identify chemotherapeutic episodes, International
Classiﬁcation of Diseases 9th Modiﬁcation (ICD-9) codes
for anemia, and hemoglobin values within each episode
and immediately preceding new anemia diagnoses.
Descriptive statistics and multivariate regression were
used to examine the relationship between anemia diag-
nosis and hemoglobin values. RESULTS: A total of 3180
chemotherapeutic episodes corresponding to 2717 oncol-
ogy patients were identiﬁed. In episodes in which the
hemoglobin dropped below 12g/dL (1689 episodes;
53%), an anemia diagnosis occurred in only 733 episodes
(45%). Additionally, an anemia diagnosis was found in
only 66% of the episodes where hemoglobin fell below
10.0g/dL. Being over 50 years old, having Non-Hodgkins
Lymphoma, and having fatigue or renal disease were
observed to increase the odds of diagnosis controlling for
hemoglobin nadir values and chemotherapeutic agent.
